The newly acquired tigecycline program complements SCT's other cancer stem cell program, SIRPaFc. The latter is an antibody-like Fc fusion protein that targets the CD47 protein with high affinity, ...

Older adults have unique risk factors for poor outcomes after hematopoietic stem-cell transplant (HSCT). We sought to determine the impact of our multidisciplinary supportive care program, Enhanced ...

JACIE pursues the same objectives as FACT (Foundation for the Accreditation of Cell Therapy), the accreditation program for hematopoietic SCT (HSCT) activities in North America; both aim at ...